Evidence map›Paper›PMID 26680365›Full record

ArticleZeitschrift fur Rheumatologie2016

[Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].

K Albrecht, J Callhoff, E Edelmann, G Schett, M Schneider, A Zink

Abstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. [Digital diagnostic support in rheumatology].Zeitschrift fur Rheumatologie · 2021
    Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

K AlbrechtDeutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. albrecht@drfz.de.
J CallhoffDeutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
E EdelmannRheumapraxis Bad Aibling, Bad Aibling, Deutschland.
G SchettMedizinische Klinik 3, Universitätsklinikum Erlangen, Erlangen, Deutschland.
M SchneiderPoliklinik und Hiller Forschungszentrum für Rheumatologie, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Deutschland.
A ZinkDeutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate remission rates and therapeutic strategies in the routine care of early rheumatoid arthritis.

methodsBetween 2010 and 2013, a total of 1,301 patients with early arthritis were followed by 89 rheumatologists for up to 2 years in an early arthritis cohort (CAPEA). Complete 2-year data are available for 669 patients with rheumatoid arthritis.

resultsNinety-three percent of patients were diagnosed with a moderate or high disease activity score (DAS28 > 3.2). Within 6 months, 40 % were in clinical remission (DAS28 < 2.6) and 21 % reached a low disease activity score (DAS28 > 2.6 to < 3.2). This proportion did not substantially increase during the 2-year follow-up. Methotrexate was the standard first-line treatment in 82 % of patients. During follow-up, 10 % were treated with a combination of disease-modifying antirheumatic drugs (DMARDs) and 12 % with biological agents. In 60 % of the patients who did not reach remission within 3 months (and 54 % of patients without remission by 6 months), treatment was not changed. At the beginning, 77 % of patients were treated with glucocorticoids at different starting doses (26 % < 7.5 mg, 29 % 7.5-20 mg, and 45 % ≥ 20 mg of prednisolone per day). After 2 years, 47 % remained on glucocorticoids.

conclusionWhile 40 % of patients achieved clinical remission through standard care within 6 months, disease activity remained moderate to high in 37 % of patients at 2 years. In these patients a more consistent application of treatment may have increased the response rates.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesGermanyGlucocorticoidsHumansLongitudinal StudiesMaleMethotrexateMiddle AgedPrevalenceRemission InductionRisk FactorsAntirheumatic AgentsGlucocorticoidsMethotrexateAntirheumatic agentsCombination drug therapyGlucocorticoidsPrognosisTreatment outcome

Identifiers

PMID26680365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.